Identificador persistente para citar o vincular este elemento: http://hdl.handle.net/10553/46617
Campo DC Valoridioma
dc.contributor.authorAspa, Javieren_US
dc.contributor.authorRajas, Olgaen_US
dc.contributor.authorDe Castro, Felipe Rodríguezen_US
dc.contributor.authorBlanquer, Joséen_US
dc.contributor.authorZalacain, Rafaelen_US
dc.contributor.authorFenoll, Asunciónen_US
dc.contributor.authorDe Celis, Rosaen_US
dc.contributor.authorVargas, Antonioen_US
dc.contributor.authorSalvanés, Francisco Rodríguezen_US
dc.contributor.authorEspaña, Pedro Pabloen_US
dc.contributor.authorRello, Jordien_US
dc.contributor.authorTorres, Antonien_US
dc.date.accessioned2018-11-23T06:24:33Z-
dc.date.available2018-11-23T06:24:33Z-
dc.date.issued2004en_US
dc.identifier.issn1058-4838en_US
dc.identifier.urihttp://hdl.handle.net/10553/46617-
dc.description.abstractA multicenter study of 638 cases of community-acquired pneumonia due to Streptococcus pneumoniae (SP-CAP) was performed to assess current levels of resistance. Of the pneumococcal strains, 35.7% had an minimum inhibitory concentration (MIC) of penicillin of ⩾0.12 µg/mL (3 isolates had an MIC of 4 µg/mL), 23.8% had an MIC of erythromycin of 128 µg/mL, and 22.2% were multidrug resistant. Logistic regression determined that chronic pulmonary disease (odds ratio [OR], 1.44], human immunodeficiency virus infection (OR, 1.98), clinically suspected aspiration (OR, 2.12), and previous hospital admission (OR, 1.69) were related to decreased susceptibility to penicillin, and previous admission (OR, 1.89) and an MIC of penicillin of MIC ⩾0.12 µg/mL (OR, 15.85) were related to erythromycin resistance (MIC, ⩾1 µg/mL). The overall mortality rate was 14.4%. Disseminated intravascular coagulation, empyema, and bacteremia were significantly more frequent among patients with penicillin-susceptible SP-CAP. Among isolates with MICs of penicillin of ⩾0.12 µg/mL, serotype 19 was predominant and was associated with a higher mortality rate. In summary, the rate of resistance to β-lactams and macrolides among S. pneumoniae that cause CAP remains high, but such resistance does not result in increased morbidity.en_US
dc.languageengen_US
dc.relation.ispartofClinical Infectious Diseasesen_US
dc.sourceClinical Infectious Diseases [ISSN 1058-4838],v. 38, p. 787-798en_US
dc.subject32 Ciencias médicasen_US
dc.subject320505 Enfermedades infecciosasen_US
dc.subject320508 Enfermedades pulmonaresen_US
dc.subject.otherErythromycinen_US
dc.subject.otherLung diseasesen_US
dc.subject.otherPenicillinen_US
dc.subject.otherBacteremiaen_US
dc.subject.otherCommunity acquired pneumoniaen_US
dc.subject.otherDisseminated intravascular coagulationen_US
dc.subject.otherEmpyemaen_US
dc.subject.otherLactamsen_US
dc.subject.otherPneumonia,en_US
dc.subject.otherPneumococcalen_US
dc.subject.otherStreptococcus pneumoniaeen_US
dc.subject.otherMacrolidesen_US
dc.subject.otherMorbidityen_US
dc.subject.otherMortalityen_US
dc.subject.otherHiv infectionsen_US
dc.subject.otherMinimum inhibitory concentration resulten_US
dc.subject.otherMinimum inhibitory concentration measurementen_US
dc.subject.otherHospital admissionen_US
dc.subject.otherMalnutrition-inflammation-cachexia syndromeen_US
dc.subject.otherSerotypeen_US
dc.titleDrug-resistant pneumococcal pneumonia: Clinical relevance and related factorsen_US
dc.typeinfo:eu-repo/semantics/articleen_US
dc.typeArticleen_US
dc.identifier.doi10.1086/381886en_US
dc.identifier.scopus2-s2.0-12144288480-
dc.contributor.authorscopusid6602555827-
dc.contributor.authorscopusid6505890335-
dc.contributor.authorscopusid55942667000-
dc.contributor.authorscopusid7004176630-
dc.contributor.authorscopusid7003514650-
dc.contributor.authorscopusid7004456790-
dc.contributor.authorscopusid6602580905-
dc.contributor.authorscopusid57196954708-
dc.contributor.authorscopusid6507201781-
dc.contributor.authorscopusid7003831102-
dc.contributor.authorscopusid7102682070-
dc.contributor.authorscopusid7401785975-
dc.description.lastpage798en_US
dc.description.firstpage787en_US
dc.relation.volume38en_US
dc.investigacionCiencias de la Saluden_US
dc.type2Artículoen_US
dc.description.numberofpages12en_US
dc.utils.revisionen_US
dc.date.coverdateMarzo 2004en_US
dc.identifier.ulpgcen_US
dc.contributor.buulpgcBU-MEDen_US
dc.description.jcr5,594
dc.description.jcrqQ1
dc.description.scieSCIE
item.fulltextSin texto completo-
item.grantfulltextnone-
crisitem.author.deptGIR IUIBS: Patología y Tecnología médica-
crisitem.author.deptIU de Investigaciones Biomédicas y Sanitarias-
crisitem.author.deptDepartamento de Ciencias Médicas y Quirúrgicas-
crisitem.author.orcid0000-0002-6812-2739-
crisitem.author.parentorgIU de Investigaciones Biomédicas y Sanitarias-
crisitem.author.fullNameRodríguez De Castro, Felipe Carlos B.-
Colección:Artículos
Vista resumida

Citas SCOPUSTM   

117
actualizado el 13-oct-2024

Citas de WEB OF SCIENCETM
Citations

98
actualizado el 13-oct-2024

Visitas

63
actualizado el 27-jul-2024

Google ScholarTM

Verifica

Altmetric


Comparte



Exporta metadatos



Los elementos en ULPGC accedaCRIS están protegidos por derechos de autor con todos los derechos reservados, a menos que se indique lo contrario.